Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Diabetic dyslipidemia

R A Kreisberg¹

¹Department of Medicine, Baptit Health System, Birmingham, Alabama 35213, USA.]

The American Journal of Cardiology

|January 23, 1999

Summary

This summary is machine-generated.

Diabetic dyslipidemia significantly increases coronary artery disease risk beyond traditional factors. Lipid-lowering therapies, particularly statins, are effective in reducing cardiac events in type 2 diabetes patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Management of hyperglycemic crises in patients with diabetes.

Diabetes care·2001

Same author

Hyperlipidemia: diagnostic and therapeutic perspectives.

The Journal of clinical endocrinology and metabolism·2000

Same author

Efficacy and safety of an extended-release niacin (Niaspan): a long-term study.

The American journal of cardiology·1999

Same author

Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia.

The American journal of cardiology·1998

Same author

Hyperlipidemia.

Current therapy in endocrinology and metabolism·1997

Same author

Cholesterol-lowering and coronary atherosclerosis: good news and bad news.

The American journal of medicine·1996

Same journal

Real-World Effectiveness and Tolerability of Sacubitril/Valsartan in Octogenarian Patients With Heart Failure: Results From the PARACHUTER Study.

The American journal of cardiology·2026

Same journal

ECG-Guided Conduction Pathways as a Lever to Shorten Post-TAVI Hospitalization.

The American journal of cardiology·2026

Same journal

Cystatin-C versus creatinine and kidney function in heart failure with preserved ejection fraction: a SOGALDI-PEF analysis.

The American journal of cardiology·2026

Same journal

Balloon-expandable versus Self-expanding Valves in Patients with Small Aortic Annuli Undergoing Transcatheter Aortic Valve Replacement.

The American journal of cardiology·2026

Same journal

Drug-Coated Balloons versus Drug-Eluting Stents following Coronary Atherectomy in Severely Calcified Lesions: A Systematic Review and Meta-Analysis.

The American journal of cardiology·2026

Same journal

Prehospital Statin Therapy and Outcomes in ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.

The American journal of cardiology·2026

See all related articles

Area of Science:

Cardiology
Endocrinology
Metabolic Syndrome

Background:

Coronary artery disease (CAD) risk is elevated in diabetes mellitus, with traditional risk factors explaining only 25-50% of this increase.
Hyperglycemia and dyslipidemia are key contributors, with lipoprotein abnormalities manifesting early and significantly impacting macrovascular disease risk.

Purpose of the Study:

To investigate the role of dyslipidemia in diabetic cardiovascular risk.
To evaluate the efficacy of lipid-lowering therapies in reducing cardiac events in patients with type 2 diabetes.

Main Methods:

Analysis of lipid and lipoprotein profiles in insulin-resistant diabetes.
Review of clinical trial data on lipid-lowering therapies (gemfibrozil, statins) for primary and secondary prevention of cardiac events in diabetic patients.

Related Experiment Videos

Main Results:

Insulin resistance in diabetes alters lipids, leading to accumulation of atherogenic particles (VLDL remnants) and reduced HDL cholesterol.
Hypertriglyceridemia, even within the normal range, is linked to small, dense LDL particles and increased atherosclerosis.
Lipid-lowering therapies demonstrated significant risk reduction for cardiac events: statins (22-50%) and fibrates (approx. 65%).
Diabetic patients showed a 1.5-1.7 fold higher risk of coronary events compared to non-diabetics.

Conclusions:

Dyslipidemia, particularly hypertriglyceridemia and altered LDL/HDL profiles, is a major driver of atherosclerotic risk in diabetes.
Lipid-lowering therapy, especially statins, is crucial for managing cardiovascular risk in type 2 diabetes.
While fibrates improve triglycerides and HDL, statins offer a better LDL-cholesterol to HDL-cholesterol ratio and are preferred for managing CAD risk in diabetics.